Pure Global AI
NCT06337305Completed

Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer

University of Kansas Medical CenterClinicalTrials.gov
Study focus
Disease/Condition
Bladder Cancer
Study type
Observational
Sponsor & location
Primary sponsor
University of Kansas Medical Center
Location
Kansas City, United States of America
Timeline & enrollment
Phase
N/A
Start date
Aug 19, 2020
End date
Aug 19, 2023
Enrollment
74 participants
Primary outcome

Change in resiliency as measured by the Connor-Davidson Resilience Scale (CD-RISC-25).,Change in quality of life in patients undergoing radical cystectomy as measured by the Functional Assessment of Cancer Therapy-Bladder-Cystectomy (FACT-Bl-Cys).,Change in quality of life in patients undergoing radical cystectomy as measured by the PROMIS-29.

Summary

This is a prospective cross-sectional survey-based study composed of both a retrospective
 chart review and 3-series patient survey. This study will help elicit potential areas
 throughout the perioperative course of radical cystectomy to improve patient resilience and
 quality of life, providing opportunity for future interventional studies.

ICD-10 classifications
Malignant neoplasm of bladderMalignant neoplasm: Bladder, unspecifiedMalignant neoplasm: Dome of bladderMalignant neoplasm: Overlapping lesion of bladderMalignant neoplasm: Lateral wall of bladder
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06337305
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06337305 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Kansas Medical Center and is currently Completed. The study focuses on Bladder Cancer. Target enrollment is 74 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.